Partnerships, Licensing, Investments and Merger and Acquisition Deals and Trends in Pharmaceuticals

• Publication date: August 2011

The report provides detailed data on partnership and licensing transactions, Merger and Acquisition s, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals market in Q2 2010. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides data on the top finan...

The report provides detailed data on partnership and licensing transactions, Merger and Acquisition s, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals market in Q2 2010. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides data on the top financial advisory firms in the pharmaceuticals market .

Data presented in this report is derived from Industry expert's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope of the Research

- Analysis of the industry trends for the pharmaceutical market in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health sectors .
- Analysis of partnerships, licensing, Merger and Acquisition s, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical market .
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and Merger and Acquisition s.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical market .
- Analysis of partnership and licensing deals based on clinical stage of development of products.
-

What's inside this report? of the pharmaceutical deals globally in the last five quarters.
- Information on the top deals happened in the pharmaceutical market .
- Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in Merger and Acquisition s and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Why Should You Get This Report?

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing sectors for investments in your market .
- Evaluate the types of industry players which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify industry players that are aggressively looking to raise capital in the industry
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical market .
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech firms .
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical market .
- Identify growth sectors and opportunities in each region within the market .
- Look for key financial advisors where you are planning to raise capital from the industry or for take over s within the market .

Global Pharmaceutical Industry

1 Table of contents 2
I. 1 List of Data tables 4
I. 2 List of Charts 6

II Deal Summary 8
II. 1 Pharmaceuticals & Healthcare, World Deals Analysis, Q2 2010 8
II. 2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals and Deal Value, Q2 2010 10
II. 3 Pharmaceuticals & Healthcare, Global, Top Deals, Q2 2010 11

III Pharmaceuticals & Healthcare, Merger and Acquisition Deal Summary, by Type 12
III. 1 Pharmaceuticals & Healthcare, Global, Merger and Acquisition, Q2 2010 12
III. 1.1 Top Merger and Acquisition Deals in Q2 2010 13
III. 1.2 Pharmaceuticals & Healthcare, World M&A Deals, by Therapy Area, Q2 2009 - Q2 2010 14
III. 2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q2 2010 15
III. 2.1 Top Secondary Offerings in Q2 2010 16
III. 2.2 Top PIPE Deals in Q2 2010 16
III. 2.3 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q2 2009 – Q2 2010 17
III. 3 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Q2 2010 18
III. 3.1 Top Public Debt Offerings in Q2 2010 19
III. 3.2 Top Private Debt Placements in Q2 2010 19
III. 3.3 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, Q2 2009 - Q2 2010 20
III. 4 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q2 2010 21
III. 4.1 Top Venture Financing Deals in Q2 2010 22
III. 4.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q2 2010 23
III. 4.3 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q2 2009 - Q2 2010 24
III. 4.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Last One Year 25
III. 4.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Firms, Q2 2010 26
III. 5 Pharmaceuticals & Healthcare, World Private Equity Deals, Q2 2010 27
III. 5.1 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q2 2009 - Q2 2010 28

IV Pharmaceuticals & Healthcare, Global, Partnership Deals, Q2 2010 29
IV. 1 Pharmaceuticals & Healthcare, Global, Partnership Deals Number of Deals and Deal Value (US$ m), Q2 2010 29
IV. 2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q2 2009 - Q2 2010 30
IV. 3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Value (US$ m), Q2 2010 31
IV. 3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Value, Q2 2010 32
IV. 3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q2 2010 32
IV. 3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q2 2010 33
IV. 4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payment and Deal Value (US$ m), Q2 2009 - Q2 2010 34
IV. 5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 35
IV. 6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Value (US$ m), Q2 2009 - Q2 2010 36

V Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q2 2010 37
V. 1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q2 2010 37
V. 2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payment and Deal Value (US$ m), Q2 2010 38
V. 2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q2 2010 39
V. 2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payment, Q2 2010 39
V. 2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q2 2010 40
V. 2.4 Pharmaceuticals & Healthcare, Global, Licensing Agreements with Equity Investment in Licensor, Q3 2009 – Q2 2010 40
V. 3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q2 2009 - Q2 2010 41
V. 4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payment Vs Milestone Payment (US$ m), Q2 2009 - Q2 2010 42
V. 5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Value (US$ m), Q2 2009 - Q2 2010 43
V. 6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payment Vs Milestone Payment (US$ m), Q2 2009 - Q2 2010 44

VI Deal Summary by Therapy Area 45
VI. 1 Pharmaceuticals & Healthcare, Oncology Deals, Q2 2010 45
VI. 1.1 Oncology – Deals of the Quarter 46
VI. 2 Pharmaceuticals & Healthcare, Central Nervous System Deals, Q2 2010 47
VI. 2.1 Central Nervous System – Deals of the Quarter 48
VI. 3 Pharmaceuticals & Healthcare, Infectious Disease Deals, Q2 2010 49
VI. 3.1 Infectious Disease – Deals of the Quarter 50
VI. 4 Pharmaceuticals & Healthcare, Immunology Deals, Q2 2010 51
VI. 4.1 Immunology – Deals of the Quarter 52
VI. 5 Pharmaceuticals & Healthcare, Cardiovascular Deals, Q2 2010 53
VI. 5.1 Cardiovascular – Deals of the Quarter 54
VI. 6 Pharmaceuticals & Healthcare, Metabolic Disorders Deals, Q2 2010 55
VI. 6.1 Metabolic Disorders – Deals of the Quarter 56
VI. 7 Pharmaceuticals & Healthcare, Respiratory Deals, Q2 2010 57
VI. 7.1 Respiratory – Deals of the Quarter 58
VI. 8 Pharmaceuticals & Healthcare, Gastrointestinal Deals, Q2 2010 59
VI. 8.1 Gastrointestinal – Deals of the Quarter 60
VI. 9 Pharmaceuticals & Healthcare, Dermatology Deals, Q2 2010 61
VI. 9.1 Dermatology – Deals of the Quarter 62
VI. 10 Pharmaceuticals & Healthcare, Genito Urinary System and Sex Hormones Deals, Q2 2010 63
VI. 10.1 Genito Urinary System and Sex Hormones – Deals of the Quarter 64

VII Deal Summary by Geography 65
VII. 1 Pharmaceuticals & Healthcare, North America Region Deals, Q2 2010 65
VII. 1.1 North America – Deals of the Quarter 66
VII. 2 Pharmaceuticals & Healthcare, Europe Region Deals, Q2 2010 67
VII. 2.1 Europe – Deals of the Quarter 68
VII. 3 Pharmaceuticals & Healthcare, Asia-Pacific Deals, Q2 2010 69
VII. 3.1 Asia-Pacific – Deals of the Quarter 70
VII. 4 Pharmaceuticals & Healthcare, Rest of the World Deals, Q2 2010 71
VII. 4.1 Rest of the World – Deals of the Quarter 72

VIII Pharmaceuticals & Healthcare, Top Advisors 73
VIII. 1 Pharmaceuticals & Healthcare, World Top Financial Advisors, Merger and Acquisition, Last One Year 73
VIII. 2 Pharmaceuticals & Healthcare, Top Financial Advisors, Equity Offerings, Last One Year 74

IX Further Information 75
IX. 1 Methodology 75
IX. 2 About GlobalData 75
IX. 3 Contact Us 76
IX. 4 Disclosure information 76
IX. 5 Disclaimer 76

1.1 List of Data tables
Data table 1: Pharmaceuticals & Healthcare, Global, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 9
Data table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Value (%), Q2 2010 10
Data table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q2 2010 11
Data table 4: Pharmaceuticals & Healthcare, Global, Merger and Acquisition, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q2 2009 – Q2 2010 12
Data table 5: Pharmaceuticals & Healthcare, Global, Top Merger and Acquisition Deals, Q2 2010 13
Data table 6: Pharmaceuticals & Healthcare, Global, Merger and Acquisition, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), by Therapy Area,, Q2 2009 - Q2 2010 14
Data table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 15
Data table 8: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q2 2010 16
Data table 9: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q2 2010 16
Data table 10: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m),, Q2 2009 - Q2 2010 17
Data table 11: Pharmaceuticals & Healthcare, Global, Debt Offering, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 18
Data table 12: Pharmaceuticals & Healthcare, Global, Top Public Debt Offerings, Q2 2010 19
Data table 13: Pharmaceuticals & Healthcare, Global, Top Private Debt Placements, Q2 2010 19
Data table 14: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Summary, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 20
Data table 15: Pharmaceuticals & Healthcare, Global, Venture Capital, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 21
Data table 16: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q2 2010 22
Data table 17: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Value (%), Q2 2010 23
Data table 18: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Merger and Acquisition Deal Summary, Q2 2009 - Q2 2010 24
Data table 19: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Value (US$ m), Q3 2009 – Q2 2010 25
Data table 20: Pharmaceuticals & Healthcare, Global, Top VC Backed Firms, Q2 2010 26
Data table 21: Pharmaceuticals & Healthcare, Global, Private Equity, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q2 2009 – Q2 2010 27
Data table 22: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Merger and Acquisition Deal Summary, Q2 2009 - Q2 2010 28
Data table 23: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 29
Data table 24: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 30
Data table 25: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payment and Deal Value (US$ m), Q2 2009 - Q2 2010 31
Data table 26: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payment and Deal Value (US$ m), Q2 2010 32
Data table 27: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q2 2010 32
Data table 28: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q2 2010 33
Data table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Value (US$ m), Q2 2009 - Q2 2010 34
Data table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q2 2009 - Q2 2010 35
Data table 31: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Value (US$ m), Q2 2009 - Q2 2010 36
Data table 32: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 37
Data table 33: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Merger and Acquisition Deal Summary, Upfront & Milestone Payment and Deal Value (US$ m), Q2 2009 - Q2 2010 38
Data table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Value, Q2 2010 39
Data table 35: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q2 2010 39
Data table 36: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q2 2010 40
Data table 37: Pharmaceuticals & Healthcare, Global, Licensing Agreements with Equity Investment in Licensor, Q3 2009 – Q2 2010 40
Data table 38: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 41
Data table 39: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q2 2009 - Q2 2010 42
Data table 40: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q2 2009 - Q2 2010 43
Data table 41: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Value (US$ m), Q2 2009 - Q2 2010 44
Data table 42: Pharmaceuticals & Healthcare, Global, Oncology, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 46
Data table 43: Pharmaceuticals & Healthcare, Global, Central Nervous System, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 48
Data table 44: Pharmaceuticals & Healthcare, Global, Infectious Disease, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 50
Data table 45: Pharmaceuticals & Healthcare, Global, Immunology, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 52
Data table 46: Pharmaceuticals & Healthcare, Global, Cardiovascular, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 54
Data table 47: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 56
Data table 48: Pharmaceuticals & Healthcare, Global, Respiratory, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 58
Data table 49: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 60
Data table 50: Pharmaceuticals & Healthcare, Global, Dermatology, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 62
Data table 51: Pharmaceuticals & Healthcare, Global, Genito Urinary System and Sex Hormones, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 64
Data table 52: Pharmaceuticals & Healthcare, North America, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 66
Data table 53: Pharmaceuticals & Healthcare, Europe, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 68
Data table 54: Pharmaceuticals & Healthcare, Asia-Pacific, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 70
Data table 55: Pharmaceuticals & Healthcare, Rest of the World, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 72
Data table 56: Pharmaceuticals & Healthcare, Top Financial Advisors, Merger and Acquisition, Number of Deals and Deal Value (US$ m), Q3 2009 – Q2 2010 73
Data table 57: Pharmaceuticals & Healthcare, World Top Financial Advisors, Equity Offerings, Number of Deals and Deal Value (US$ m), Q3 2009 – Q2 2010 74

1.2 List of Charts
Chart 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 8
Chart 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%) and Deal Value (%), Q2 2010 10
Chart 3: Pharmaceuticals & Healthcare, Global, Merger and Acquisition, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 12
Chart 4: Pharmaceuticals & Healthcare, Global, Merger and Acquisition, by Therapy Area, Number of Deals and Deal Value (US$ m), by Therapy Area, Q2 2009 – Q2 2010 14
Chart 5: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 15
Chart 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Value (US$ m),, Q2 2009 – Q2 2010 17
Chart 7: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 18
Chart 8: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, Number of Deals and Deal Value (US$ m),, Q2 2009 - Q2 2010 20
Chart 9: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 21
Chart 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%) and Deal Value (%), Q2 2010 23
Chart 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Value (US$ m), by Therapy Area, Q2 2009 - Q2 2010 24
Chart 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Value (US$ m), Q3 2009 – Q2 2010 25
Chart 13: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Value (US$ m), Q2 2009 – Q2 2010 27
Chart 14: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Value (US$ m), by Therapy Area, Q2 2009 - Q2 2010 28
Chart 15: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 29
Chart 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 30
Chart 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Value (US$ m), Q2 2009 - Q2 2010 31
Chart 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Value (US$ m), Q2 2009 - Q2 2010 34
Chart 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q2 2009 - Q2 2010 35
Chart 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Value (US$ m), Q2 2009 - Q2 2010 36
Chart 21: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 37
Chart 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payment and Deal Value (US$ m), Q2 2009 - Q2 2010 38
Chart 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 41
Chart 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payment and Deal Value (US$ m), Q2 2009 - Q2 2010 42
Chart 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 43
Chart 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payment and Deal Value (US$ m), Q2 2009 - Q2 2010 44
Chart 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 45
Chart 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 47
Chart 29: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 49
Chart 30: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 51
Chart 31: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 53
Chart 32: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 55
Chart 33: Pharmaceuticals & Healthcare, Global, Respiratory, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 57
Chart 34: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 59
Chart 35: Pharmaceuticals & Healthcare, Global, Dermatology, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 61
Chart 36: Pharmaceuticals & Healthcare, Global, Genito Urinary System and Sex Hormones, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 63
Chart 37: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 65
Chart 38: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 67
Chart 39: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 69
Chart 40: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Value (US$ m), Q2 2009 - Q2 2010 71
Chart 41: Pharmaceuticals & Healthcare, Top Financial Advisors, Merger and Acquisition, Number of Deals and Deal Value (US$ m), Q3 2009 – Q2 2010 73
Chart 42: Pharmaceuticals & Healthcare, World Top Financial Advisors, Equity Offerings, Number of Deals and Deal Value (US$ m), Q3 2009 – Q2 2010 74

Companies mentioned

Pharmaceutical in World

Cuba Poisonings, 45-59 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pharmaceutical
• Countries : Cuba, World

Fiji Poisonings, 70+ Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pharmaceutical
• Countries : Fiji, World

Cook Islands Poisonings, 45-59 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pharmaceutical
• Countries : World

Iran Poisonings, 30-44 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pharmaceutical
• Countries : Iran, World

Saint Vincent Poisonings, 15-29 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pharmaceutical
• Countries : World